Edwards' sapien 3 ultra resilia valve demonstrates continued excellent outcomes for patients in real world data

London--(business wire)--edwards lifesciences (nyse: ew) today announced one-year data highlighting the continued outstanding performance of its sapien 3 ultra resilia valve. the data were presented at pcr london valves 2024 and simultaneously published in the journal of the american college of cardiology (jacc): cardiovascular interventions. an analysis of data from more than 9,000 propensity-matched patients in the sts/acc tvt registry1 demonstrated that those who received edwards' newest gen.
EW Ratings Summary
EW Quant Ranking